New system developed that can switch on immune cells to attack cancer cells

December 7, 2016

Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target. This method has potential to be used as a future cancer immunotherapy treatment as well as providing more insight into how immune cells are activated to find and kill cancer cells. The findings are presented today at the Joint Congress of the British and Dutch Societies for Immunology, taking place in Liverpool, UK.

Immunotherapies—which make the body's own attack cancer —are one of the most promising new forms of cancer treatment. For these to be effective, we need to understand how the immune system identifies cancer cells and reacts to them. This requires the protein (or antigen) on the to be presented for inspection by antigen presenting cells (APCs), a group of immune cells that are responsible for co-ordinating the immune response. They effectively assess threats to the body by gathering information from proteins they encounter. They then use this information to instruct the immune system's T cells which proteins they should react against, thus starting the immune responses. Although natural APCs produced by the human body have been used for immunotherapies, they need to be developed separately for each individual, which is costly, time consuming and has only shown variable results.

PhD student Loek Eggermont and team from the Figdor lab at Radboud University Medical Centre in The Netherlands sought to solve this problem by developing artificial antigen presenting cells instead. They developed a filamentous polymer scaffold, with a nanoworm-like structure, that mimics the of antigen presenting cells. This scaffold has various T cell activating proteins embedded in it. Through in vitro studies, they found that these artificial APCs are able to activate human T cells, influencing both their proliferation and differentiation. They also found that different receptors on T cells must be triggered in close proximity to one another by proteins attached to artificial APCs to achieve optimal activation of the T cells.

These findings help us better understand the mechanisms behind T cell activation - ie what signals these cells need to start attacking cancer cells—and as well as providing a promising avenue of research for developing more efficient immunotherapies. The team now aim to make this polymer more specific to cancer proteins, so that it will induce T cells to only attack . Following this, the system then needs to be tested in a mouse model as a first assessment of whether it can be used to treat cancer in vivo effectively.

Researcher Loek Eggermont from Radboud University Medical Centre said: "Cancer immunotherapy strongly depends on proper activation of , such as T cells, to find and destroy the tumour cells. Right now, immunotherapies to fight cancer mostly depend on non-specific activation of the immune system.

"We have shown that an artificial antigen presenting cell can be effective in activating T cells in in vitro studies. Our findings also help us to better understand the mechanisms behind this T cell activation. Although more studies are now needed to see if this system works in animal models, we hope that it might one day lead towards development of new off-the-shelf cancer immunotherapies."

Explore further: Cancer cells play hide-and-seek with immune system

Related Stories

Engineering the immune system to kill cancer cells

June 15, 2016

In late 2015, former President Jimmy Carter announced that he was free of the metastatic melanoma that had spread to his liver and brain. In addition to surgery and radiation, Carter was treated with an immunotherapy drug, ...

Recommended for you

A new weapon for the war on cancer

June 28, 2017

Cancerous tumors are formidable enemies, recruiting blood vessels to aid their voracious growth, damaging nearby tissues, and deploying numerous strategies to evade the body's defense systems. But even more malicious are ...

The gene behind follicular lymphoma

June 28, 2017

Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.